DotBio

DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University.

Company NameDotBio Singapore
Brand NameDotBio
IndustriesBiotech
Year of Establishment2018
Founder(s)Ignacio Asial
P?ÑR NORDLUND
No. of Employeesless than 10
Regional CoverageSingapore
Clients/
StageSeed
Investor(s)Enterprise Singapore
Futec Biomedical Investments Limited
Fundraising History184K USD (Dec 2018)
2.3M USD (Jul 2018)
Raising Fund/
Fundraising target/
Pre-money valuation/
Post-money Valuation/
Media ExposureBSA bureau
market screener
bioworld.com
sipii.sdll.cn
Company Email[email protected]

[dcb id=160440]

Leave a Reply

Your email address will not be published. Required fields are marked *